Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104377 · ClinicalTrials.gov registry record · Phase 2
Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen
A Phase 2 study of Type I Hypersensitivity, sponsored by Allergy Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 11
- Study locations
NCT00104377: Completed Phase 2 study of Type I Hypersensitivity, sponsored by Allergy Therapeutics.
NCT00104377 is a Phase 2 study of Type I Hypersensitivity that has completed, run by Allergy Therapeutics. The registered enrollment target is 70 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00104377, a Phase 2 study of Type I Hypersensitivity, has completed, sponsored by Allergy Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 11
- Study locations
Study Summary
Grass MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to grass and rye pollen. Different doses of Grass MATA will be administered and immunological changes following this treatment will be assessed.
Conditions Studied
Interventions
- BIOLOGICAL Grass MATA MPL
Study Locations (11)
Oregon
- Clinical Research Institute of Southern Oregon, PC - Medford
- Allergy Associates Research Center - Portland
Pennsylvania
- Allergy and Clinical Immunology Associates - Pittsburgh
- Asthma and Allergy Research Associates - Upland
Kansas
- College Park Family Care Center Multi-Specialty Clinical Research - Overland Park
Massachusetts
- Northeast Medical Research Associates - North Dartmouth
Missouri
- Midwest Clinical research, LLC - St Louis
Nebraska
- Allergy, Asthma, and Immunology Assoc. PC - Lincoln
New Jersey
- Asthma, Sinus, and Allergy Centers, LLC - Tinton Falls
Ohio
- Bernstein Clinical Research Center, LLC - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
What the finished NCT00104377 record still lists
NCT00104377 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Type I Hypersensitivity appearing as the primary indexed condition, and to 1 intervention - of which Grass MATA MPL is the first listed.
NCT00104377 lists 11 locations in 9 states (Oregon, Pennsylvania, Kansas).
Frequently Asked Questions
What is clinical trial NCT00104377 about?
NCT00104377 is a clinical study titled "Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen". Grass MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to grass and rye pollen. Different doses of Grass MATA will be administered and immunological changes following this treatment will be assesse...
What is the current status of trial NCT00104377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2005-03. Estimated completion is 2005-11.
What conditions does trial NCT00104377 study?
This clinical trial studies the following conditions: Type I Hypersensitivity.
What interventions are being tested in trial NCT00104377?
The interventions under investigation include: Grass MATA MPL (BIOLOGICAL).
Who is sponsoring clinical trial NCT00104377?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00104377 being conducted?
This trial has 11 study locations across Kansas, Massachusetts, Missouri, Nebraska, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type I Hypersensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00104377's enrollment target sits among peer trials
70 937th of 2000 higher than 1,036 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia